Edward Reilly

5PUBLICATIONS
46CO-AUTHORS
Gene and molecular therapyMolecular targetsMedical devicesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 28, 2025
ABBV-303 Is an NK-cell Engager Specific for c-Met-Expressing Tumors.

Jennifer D Stone, Kamonwan Fish, Devika Ashok

|May 14, 2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.

Sonia Jain, Jessica I Griffith, Kendra A Porath

|Jun 09, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.

Adam S Chervin, Jennifer D Stone, Iwona Konieczna

|Aug 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.

Mark G Anderson, Hugh D Falls, Michael J Mitten

|Mar 05, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.

John H Strickler, Patricia LoRusso, Ravi Salgia

Pageof 1

Frequent Collaborators

2 joint publications

Adam S Chervin

2 joint publications

Jennifer D Stone

2 joint publications

Joann P Palma

2 joint publications

Cormac Cosgrove